Skip to main content
. 2022 Feb 24;81(6):823–830. doi: 10.1136/annrheumdis-2021-221640

Figure 1.

Figure 1

Kaplan-Meier plots of treatment persistence with ustekinumab versus TNFi (A) Overall, (B) By sex, (C) By treatment line, (D) By presence/absence of methotrexate and (E) By extent of skin involvement at baseline. BSA, body surface area; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.